ONCOCLINICAS (ONCO3) Main Indicators
Basic Data - ONCO3
| Company | ONCOCLINICAS |
| Corporate Name | ONCOCLINICAS DO BRASIL SERVICOS MEDICOS S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Exploração de serviços médicos. participação em outras sociedades. nacionais ou estrangeiras. pesquisa e desenvolvimento experimental em ciências físicas e naturais. intermediação em pesquisa clínica. |
| Share | ONCO3 |
| Quote Date | 11/19/2024 |
| Share Type | ON |
| Last Closing | R$ 3.69 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 17.50 M |
| Last Statement | ITR - 09/30/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | IBRA, ICON, IGC, IGCT, IGNM, ITAG, SMLL |
| Updated 11/21/2024 | |
Relative Prices - ONCO3
| Price/Earnings | 33.69 |
| Price/SBV | 0.63 |
| Price/Net Sales | 0.39 |
| Price/CFO | -5.70 |
| Price/FCF | -3.63 |
| Price/Total Assets | 0.20 |
| Price/EBIT | 3.20 |
| Price/Working Capital | 0.98 |
| Price/NCAV | -0.40 |
| EV/EBIT | 10.08 |
| EV/EBITDA | 7.38 |
| EV/Net Sales | 1.24 |
| EV/CFO | -17.95 |
| EV/FCF | -11.42 |
| EV/Total Assets | 0.62 |
| Company Market Cap | R$ 2.40 B |
| Enterprise Value | R$ 7.57 B |
| Current Financial Statement Date | 09/30/2024 |
| Current Share Price | R$ 3.69 |
| Share Price Date | 11/19/2024 |
| Dividend Yield | 0.00% |
| Updated 11/21/2024 | |
Income Statement - ONCO3
| Net Revenue | R$ 6.10 B |
| Gross Result | R$ 2.04 B |
| EBIT | R$ 750.57 M |
| Depreciation and Amortization | - R$ 275.34 M |
| EBITDA | R$ 1.03 B |
| Net Profit | R$ 71.39 M |
| Net Profit/Share | R$ 0.11 |
| Updated 11/13/2024 | |
| Net Revenue | R$ 1.63 B |
| Gross Result | R$ 548.09 M |
| EBIT | R$ 190.85 M |
| Depreciation and Amortization | - R$ 72.08 M |
| EBITDA | R$ 262.93 M |
| Net Profit | - R$ 15.94 M |
| Profit/Share | - R$ 0.02 |
| Updated 11/13/2024 | |
Price and Volume Behavior - ONCO3
| Lowest Price 52 weeks | R$ 3.66 |
| Highest Price 52 weeks | R$ 13.00 |
| Variation 2024 | -70.48% |
| Variation 1 year | -63.06% |
| Variation 2 years(total) | -48.25% |
| Variation 2 years(yearly) | -28.00% |
| Variation 3 years(total) | -60.02% |
| Variation 3 years(yearly) | -26.31% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 19.22 M |
| Updated 11/21/2024 | |
Returns and Margins - ONCO3
| Return on Initial Tangible Capital | 18.86% |
| Return on Initial Invested Capital | 9.38% |
| Pre-Tax Return on Initial Tangible Capital | 28.58% |
| Pre-Tax Return on Initial Invested Capital | 14.22% |
| Return on Initial Shareholder´s Equity | 3.22% |
| Return on Initial Asset | 0.83% |
| Gross Margin | 33.54% |
| Net Margin | 1.17% |
| EBIT Margin | 12.31% |
| EBITDA Margin | 16.83% |
| Initial Asset Turnover | 0.71 |
| Financial Leverage | 3.24 |
| Liabilities/Net Worth | 2.24 |
| Net Debt/EBITDA | 5.03 |
| Updated 11/13/2024 | |
Balance Sheet - ONCO3
| Cash and Cash Equivalents | R$ 621.40 M |
| Total Assets | R$ 12.27 B |
| Short-Term Debt | R$ 955.47 M |
| Long-Term Debt | R$ 4.83 B |
| Gross Debt | R$ 5.79 B |
| Net Debt | R$ 5.16 B |
| Shareholder´s Equity | R$ 3.79 B |
| Share Book Value | R$ 5.82 |
| Common Shares | 651,756,313 |
| Preferred Shares | 0 |
| Total | 651,756,313 |
| Common Shares in Treasury | 18,963,632 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 18,963,632 |
| Common Shares (Except Treasury) | 632,792,681 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 632,792,681 |
| Updated 11/13/2024 | |
Cash Flow - ONCO3
| Operating Cash Flow | - R$ 421.64 M |
| Cash Flow from Investments | - R$ 2.16 B |
| Financing Cash Flow | R$ 2.65 B |
| Increase (Reduction) in Cash and Equivalents | R$ 70.88 M |
| Updated 11/13/2024 | |
| Operating Cash Flow | R$ 112.14 M |
| Cash Flow from Investments | R$ 31.02 M |
| Financing Cash Flow | - R$ 72.38 M |
| Increase (Reduction) in Cash and Equivalents | R$ 70.81 M |
| Updated 11/13/2024 | |
Experimental - ONCO3
| CAPEX 3 months | - R$ 53.99 M |
| Free Cash Flow 3 months | R$ 58.15 M |
| CAPEX 12 months | - R$ 240.96 M |
| Free Cash Flow 12 months | - R$ 662.60 M |
| Updated 11/13/2024 | |